{
    "Clinical Trial ID": "NCT00470847",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Lapatinib,Whole Brain Radiation,Herceptin",
        "  Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically-confirmed invasive breast cancer",
        "  HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry, or HER2 gene amplification by FISH",
        "  At least one parenchymal brain metastasis",
        "  Disease progression in the CNS as assessed by at least one of the following; new neurological signs or symptoms; new lesion(s) in the CNS on an imaging study; progressive lesions on an imaging study",
        "  At least two weeks since prior radiotherapy, last chemotherapy, immunotherapy, biologic therapy, or major surgery for cancer",
        "  18 years of age or older",
        "  Life expectancy of greater than 12 weeks",
        "  ECOG performance status 0-2",
        "  Normal organ and marrow function as described in the protocol",
        "  Left ventricular ejection fraction > 50%",
        "  Able to swallow and retain oral medications",
        "Exclusion Criteria:",
        "  Prior WBRT",
        "  Receiving any other investigational agents",
        "  Concurrent chemotherapy, immunotherapy, biologic therapy or hormonal therapy for treatment of their cancer",
        "  History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition to herceptin or lapatinib",
        "  Leptomeningeal carcinomatosis as the only site of CNS involvement",
        "  Concurrent treatment with medications that are either inducers of inhibitors of CYP3A4",
        "  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or active ulcerative colitis",
        "  History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents",
        "  Other known contraindication to MRI",
        "  Uncontrolled intercurrent illness",
        "  History of other active malignancy except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix",
        "  Pregnant or breastfeeding women"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer.",
        "  The maximum tolerated dose is defined as :The highest dose of a drug or treatment that does not cause unacceptable side effects.",
        "  Time frame: 5 Years",
        "Results 1: ",
        "  Arm/Group Title: Lapatinib,Whole Brain Radiation,Herceptin",
        "  Arm/Group Description: Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly",
        "  Overall Number of Participants Analyzed: 35",
        "  Measure Type: Number",
        "  Unit of Measure: milligrams  1250"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 8/27 (29.63%)",
        "  Diarrhea 2/27 (7.41%)",
        "  Vomiting 2/27 (7.41%)",
        "  Hypoxia 1/27 (3.70%)",
        "  Sinusitis 1/27 (3.70%)",
        "  Pulmonary Embolus 2/27 (7.41%)"
    ]
}